Breaking News

Aptar CSP’s N-Sorb Accepted to FDA’s Emerging Tech Program

Leverages Aptar's 3-Phase Activ-Polymer platform technology to help address concerns related to N-nitrosamine impurities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptar CSP Technologies, part of AptarGroup, Inc. announced that its N-Sorb nitrosamine mitigation solution has been accepted into the U.S. FDA Emerging Technology Program (ETP), which aims to help promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.   N-Sorb leverages Aptar CSP Technologies’ 3-Phase Activ-Polymer platform technology to address the pressing issue of N-nitrosamine impurities in pharmaceuticals. These impurities, classified as probable...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters